Phase Iii Study of Intermittent Monotherapy Versus Continuous Combined Androgen Deprivation

Silva, Fernando E Calais da; Silva, Fernando M. Calais da; Gonçalves, Frederico Bastos; Santos, Abel; Kliment, J.; Whelan, Peter I; Antoniou, N.; Pastidis, S.; Queimadelos, Anton Marques; Compostela, Santiago de; Robertson, Chris

doi:10.1016/s0022-5347(09)60660-1

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several trials, including various phase II studies and interim analyses of phase III trials have suggested improvement in terms of QOL, cardiovascular events and osteoporosis, among other benefits, with IAS [59,60]. Rates of OS and progression to CRPC seem to be equivalent to those seen with CAS, according to several phase II trials and early phase III data [61].…”

Section: B Intermittent Androgen Suppression (Ias)mentioning

confidence: 99%

Current Medical and Surgical Options for Androgen Deprivation in Prostate Cancer Patients

Bayraktar¹,

A²

2010

TOPCANJ

View full text Add to dashboard Cite

Abstract:The growth of prostate cancer cells is driven by androgens. Thus, androgen deprivation, is one of the main treatment modalities in the management of prostate cancer. Historically, bilateral orchiectomy, which achieves 95% reduction of testosterone levels within 3 hours, was the only effective androgen deprivation therapy (ADT). In the 1980s, luteinizing hormone-releasing hormone agonists (LHRH-A) were introduced to reduce testosterone to castration levels. After the 1980s, nonsteroidal antiandrogens were developed in addition to steroidal antiandrogens. Since then, so-called maximum androgen blockade (MAB)/combined androgen blockade (CAB), which is a combination of surgical or medical castration and oral antiandrogens, has been suggested. More recently, novel treatment modalities have been developed, such as intermittent androgen suppression (IAS), nonsteroidal antiandrogen monotherapy, and alternative antiandrogen therapy after relapse from the initial MAB/CAB. ADT, whether surgical or medical, provides important quality of life (QOL) benefits in patients with advanced and metastatic prostate cancer. While the principle of the therapy has remained unchanged, the role, type and timing of these therapies is continuously evolving. This review will focus on the current medical and surgical options for ADT in advanced and metastatic prostate cancer, summarizing the results of several recent clinical trials and discuss their implications for clinical practice and for future research in this disease.

show abstract

Section: B Intermittent Androgen Suppression (Ias)mentioning

confidence: 99%